• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

Expert: Availability of multiple PSMA agents “a boon” for patients

Video

“I think the prostate cancer community has benefited a lot in the past several years with the advent of enhanced imaging tools to help us better stage patients with prostate cancer both at their initial diagnosis and if, unfortunately, they have a recurrence,” says Edward M. Schaeffer, MD, PhD.

In this video, Edward M. Schaeffer, MD, PhD, discusses the emergence of prostate-specific membrane antigen-targeting agents in prostate cancer. Schaeffer is chair and Harold Binstein Professor of Urology at Northwestern University Feinberg School of Medicine in Chicago, Illinois.

Transcription:

Please discuss the emergence of PSMA-targeting agents in prostate cancer.

I think the prostate cancer community has benefited a lot in the past several years with the advent of enhanced imaging tools to help us better stage patients with prostate cancer both at their initial diagnosis and if, unfortunately, they have a recurrence. So there are now 3 FDA-approved PSMA-linked compounds that can be used to more accurately stage patients with prostate cancer across different areas of their care continuum, so at their initial diagnosis, and also if they had previously been treated and develop a recurrence. I think in general, there are some subtle differences between the compounds and how they "behave" in terms of their solubility, lipid vs water soluble and therefore how they're excreted. Also, there are some subtle differences in terms of just how you see them with the radiotracers that they're linked to. Big picture: I think there are now 3 compounds on the market. They all have really great, relatively overlapping applicability, which is super for the providers and the patients because they now have choices, and I appreciate that in certain regions, there may be limitations to getting access to one of them. So having 3 of them on the market is really a boon for the patients that we take care of.

This transcript was edited for clarity.

Related Videos
Blurred interior of hospital |  Image Credit: © jakkapan - stock.adobe.com
Laura Bukavina, MD, MPH, answers a question during a Zoom video interview
Image of kidneys | Image Credit: © peterschreiber.media - stock.adobe.com
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
DNA helix | Image Credit: © Siarhei - stock.adobe.com
Related Content
© 2024 MJH Life Sciences

All rights reserved.